Torrent Pharmaceuticals shares were trading in the green on 27 September after the company refuted claims that one of its products failed a quality test. 

The company has refuted all claims that one of its products, Shelcal 500, has failed a quality test by the Central Drug Standards Control Organization (CDSCO). This comes after the CDSCO found over 50 drugs, including one batch of Shelcal 500, to be Not of Standard Quality during its monthly drug alert for August 2024. 

Shelcal 500’s main ingredients are calcium and vitamin D3, and it is a dietary supplement that is used for managing vitamin D and calcium deficiency. 

However, Torrent Pharma said that the sample size seized by the regulatory body was spurious and that the company had not manufactured it. While the CDSCO notification states that the manufacturer of the seized batch of Shelcal 500 to be Pure and Cure Healthcare, based in Haridwar, Uttarakhand.

To verify the genuineness of the sample collected by CDSCO, an evaluation was conducted, said Torrent. “The outcome of the analysis concluded that the sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious.”

As to Torrent’s statement, it has inserted QR tags that display the batch production details to verify authenticity, which was found to be lacking in the confiscated Shelcal samples. Torrent has already forwarded the assessment report and response to CDSCO.

The “not of standard quality” (NSQ) product list includes well-known pharmaceuticals like the calcium supplement Shelcal, the anti-diabetic drug Glimepiride, the antacid Pan D, and the high blood pressure drug Telmisartan.

At 12:32 pm, the shares of Torrent Pharma were trading 0.03% higher at Rs 3,413.45 on NSE.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!